ARA-290 for Neuropathy: What the Evidence Shows
What human and animal studies show about ARA-290 for neuropathy, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 3
- with an outcome for neuropathy, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 2
- with an outcome for neuropathy, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 5
- with an outcome for neuropathy
Evidence for neuropathy
Each row is an outcome related to neuropathy from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Corneal nerve fiber area (4 mg) | Placebo-corrected corneal nerve fiber area change at day 28 was 109 (1 mg), 697 (4 mg, P = 0.012) and 431 (8 mg); only the 4 mg group reached significance. | Human RCTn = 64 | Investigative ophthalmology & visual science 2017, PMID 28475703 |
| Pain | Pain improved in all groups; the placebo-corrected decrease in the 4 mg group among those with moderate-severe pain was not statistically significant (P = 0.157). | Human RCTn = 64 | Investigative ophthalmology & visual science 2017, PMID 28475703 |
| Neuropathic symptoms | PainDetect neuropathic symptom scores improved significantly with ARA 290. | Human controlled trial | Molecular medicine 2015, PMID 25387363 |
| Small fiber neuropathy symptom score | The ARA 290 group improved significantly more than placebo on the small fiber neuropathy screening list score at week 4 (change -11.5 versus -2.9). | Human RCTn = 22 | Molecular medicine 2012, PMID 23168581 |
| Pain intensity (BPI) and fatigue | Brief Pain Inventory and fatigue scores improved in both groups, with no difference between treatment and placebo. | Human RCTn = 22 | Molecular medicine 2012, PMID 23168581 |
| Mechanical allodynia | ARA290 prevented the development of mechanical allodynia in the neuritis model; heat hyperalgesia was not significantly affected. | Animal · rat (not a human result) | Neuroscience 2013, PMID 23262243 |
| Neuropathic pain (allodynia) | ARA290 gave long-term relief of tactile and cold allodynia in rats, lasting as long as 15 weeks. | Animal · rat and mouse (including beta-common receptor knockout mice) (not a human result)n = 8 | Anesthesiology 2011, PMID 21873879 |
ARA-290 and neuropathy are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What peripheral neuropathy is
MedlinePlus defines peripheral nerve disorders as damage to one or more peripheral nerves, which may then fail to carry messages correctly or at all.[6]
MedlinePlus names diabetes as the most common cause of peripheral nerve disorders.[6]
Human neuropathy trials of ARA 290 (cibinetide)
In a small double-blind pilot, 22 people with sarcoidosis and small fiber neuropathy symptoms received ARA 290 2 mg or placebo three times a week intravenously for 4 weeks; the ARA 290 group improved more on the neuropathy symptom score.[3]
In a phase 2 trial in type 2 diabetes with painful neuropathy, ARA 290 4 mg or placebo was self-injected under the skin daily for 28 days, and neuropathic symptoms on the PainDetect questionnaire improved significantly in the ARA 290 group.[2]
A 64-person phase 2b trial in sarcoidosis-related small nerve fiber loss tested cibinetide at 1, 4 or 8 mg a day against placebo for 28 days, with change in corneal nerve fiber area as the primary endpoint.[1]
Animal pain studies
In rats with a spared-nerve injury, ARA290 injections gave relief of touch and cold pain behaviour lasting as long as 15 weeks, an animal result that did not occur in mice lacking the beta-common receptor.[5]
In a rat model of nerve inflammation (neuritis), ARA290 at 30 or 120 micrograms per kilogram prevented the development of mechanical allodynia but did not significantly affect heat hyperalgesia.[4]
Other peptides people research for neuropathy
No other peptide in our index has a neuropathy page yet.
All peptides for neuropathy, comparedCommon questions
Does ARA-290 help with neuropathy?
The strongest study we summarise for neuropathy is human rct evidence, across 5 studies with an outcome for neuropathy. A trial result is not an approval; see the legal status.
Is ARA-290 approved for neuropathy?
No. ARA-290 is not FDA approved for any use, including neuropathy.
What is the best peptide for neuropathy?
There is no single answer. Our neuropathy overview compares each candidate by evidence grade and legal status rather than by popularity.
Does ARA 290 help neuropathy?
Small phase 2 trials reported symptom-score improvements in sarcoidosis and in type 2 diabetes, and the authors of the diabetes trial said it deserves continued clinical evaluation.[2]
Is the animal pain data about people?
No. The long-lasting relief of allodynia was measured in rats and mice.[5]
More on ARA-290
Sources
- 1Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
- 2ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026
- 3Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
- 4The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model.Neuroscience · 2013PMID 23262243Accessed 2 Oct 2026
- 5ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.Anesthesiology · 2011PMID 21873879Accessed 2 Oct 2026
- 6Official web pageOfficial web page · web page
Found an error? Report a correction.